In order to determine whether SOX11 could serve as a molecular target antigen for glioma-specific CD8+ T cells, potential HLA-A*0201 ligands were selected from the amino acid sequence of SOX11 using 11 HLA ligand prediction algorithms, identified through the MHC combine tool (https://mhccombine.dkfz.de/mhccombine/, accessed on 14 July 2017, and again on 2 May 2022) [23]. The gene discussed is CD8A; the disease is central nervous system cancer.